SEC Form 6-K filed by Connect Biopharma Holdings Limited
$CNTB
Biotechnology: Pharmaceutical Preparations
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________________________________________________________
FORM 6-K
______________________________________________________________________
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2024
______________________________________________________________________
Commission File Number: 001-40212
______________________________________________________________________
Connect Biopharma Holdings Limited
(Translation of registrant's name into English)
______________________________________________________________________
12265 El Camino Real, Suite 350
San Diego, CA 92130, USA
(Address of principal executive office)
______________________________________________________________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
Departure of Directors or Certain Officers
As of August 12, 2024, Connect Biopharma Holdings Limited (the “Company”) appointed Lisa Peraza as Vice President, Finance. Prior to the Company, Ms. Peraza was Vice President, Chief Accounting Officer at Heron Therapeutics as well as held key finance and accounting positions at Ardea Biosciences Inc. and La Jolla Pharmaceutical Company. Ms. Peraza began her career with KPMG LLP and received a B.A. degree from the University of California, Santa Barbara and is a licensed C.P.A. in the State of California.
As part of the Company’s executive restructure, Steven Chan, the Company’s Chief Financial Officer will step down as of September 13, 2024. Mr. Chan’s departure is not the result of any disagreement with the Company on any matter related to its operations, policies or practices. Ms. Peraza will lead the Company’s finance and accounting functions after Mr. Chan’s departure.
This Report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3 (File No. 333-264340) and Form S-8 (File Nos. 333-254254 and 333-266006) of the Company, filed with the Securities and Exchange Commission, and to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Dated: September 6, 2024 | CONNECT BIOPHARMA HOLDINGS LIMITED | |||||||||||||||||||
| By | /s/ David Szekeres | |||||||||||||||||||
| Name: | David Szekeres | |||||||||||||||||||
| Title: | President | |||||||||||||||||||